SCHEMBL6078852

SCHEMBL6078852

Cc1ccc(OS(=O)(=O)c2ccc(NS(=O)(=O)c3ccc4ccc(NC(=O)Nc5ccc6ccc(S(=O)(=O)Nc7ccc(S(=O)(=O)Oc8ccc(C)cc8)cc7)cc6c5)cc4c3)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 4/20 0.58
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
LMNA P02545 3/20 0.52
ALOX12 P18054 2/20 0.52
ALDH1A1 P00352 2/20 0.52
ENPP3 O14638 3/20 0.50
ENPP1 P22413 3/20 0.50
MAPT P10636 2/20 0.50
TP53 P04637 1/20 0.50
POLB P06746 1/20 0.50
XBP1 P17861 1/20 0.50
HTT P42858 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078470 0.91 ENPP2 (0.53) ENPP2MEN1KMT2ALMNAALOX12
SCHEMBL6079936 0.87 ENPP2 (0.50) ENPP2MEN1KMT2ALMNAALOX12
SCHEMBL22187429 0.85 ENPP2 (0.75) ENPP2MEN1KMT2ALMNAENPP3
SCHEMBL22187256 0.83 ENPP2 (0.67) ENPP2MEN1KMT2ALMNAALOX12
SCHEMBL22588889 0.79 ENPP2 (0.63) ENPP2MEN1KMT2ALMNAALDH1A1
SCHEMBL29673656 0.79 ENPP2 (0.60) ENPP2MEN1KMT2ALMNAENPP3
SCHEMBL22187545 0.79 ENPP2 (0.60) ENPP2MEN1KMT2ALMNAENPP3
SCHEMBL30540127 0.78 ENPP2 (0.59) ENPP2MEN1KMT2ALMNAENPP3
SCHEMBL22187574 0.78 ENPP2 (0.59) ENPP2MEN1KMT2ALMNAENPP3
SCHEMBL22187359 0.78 ENPP2 (0.62) ENPP2MEN1KMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071231-B2 Naphthalene ureas as glucose uptake enhancers TELIK, INC. (US) 2006-07-04 US disclosed
EP-1181271-B1 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2005-01-19 EP disclosed
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers SPEVAK WAYNE R (US) 2003-07-17 US disclosed
US-6458998-B1 NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS TELIK, INC. 2002-10-01 US disclosed
EP-1181271-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS Telik, Inc. (US) 2002-02-27 EP disclosed
WO-2000071506-A9 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2001-09-20 WO disclosed
WO-2000071506-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK, INC. (US) 2000-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers GPR119, SLC2A8, SLC2A1 ENPP2 3135/4885MEN1 3696/4885KMT2A 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.